In this webinar, the second in a series of toxicology sessions, InSphero Director of Business Development Dr. Sue Grepper discusses why drug-induced liver injury (DILI) remains a major cause of drug attrition in the pharmaceutical industry.
Sue provides guidelines for integrating human 3D liver models into the drug development workflow for efficient screening for DILI compounds earlier in the preclinical phase, using our 3D InSight™ Liver Toxicology Platform as an example.
You will learn:
- Why human 3D liver models outperform traditional 2D hepatocyte cultures
- Requirements for predictive DILI screening using human 3D liver models
- Industry trends and future outlook for predictive liver toxicology